Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

After 3 years 80 of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72 of men who received standard care Chicago 8211 Enzalutamide an oral androgen receptor inhibit [...]

Zytig Treatment Prolongs Survival in Advanced Prostate Cancer

Zytig Abiraterone acetate plus prednisone and androgen deprivation therapy ADT significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer CSPC About Zytig Zyt [...]